Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy

J Clin Oncol. 2023 Jan 10;41(2):170-172. doi: 10.1200/JCO.22.01711. Epub 2022 Oct 20.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal*
  • Cost Savings
  • Cost-Benefit Analysis
  • Humans
  • Immunotherapy*

Substances

  • Antibodies, Monoclonal